The market's growth is primarily attributed to the increasing prevalence of liver diseases and the growing focus on developing alternatives for animal testing models. However, the high costs of human liver models and issues with incorporating liver models into existing workflow are hindering the Human Liver Models market growth. The liver is an important organ that performs vital body functions such as synthesis of blood clotting factors, bile production, protein production, and detoxification. Human liver models are used to study the drug's toxicity and enable understanding of the effect of drugs and the progression of liver disease. The rising focus on developing alternatives for the animal testing models is one of the major factors estimated to encourage the growth of the global human liver models in the next few years.
The Asia Pacific biopharmaceutical industry was disturbed for a few months of 2020, owing to the COVID-19 outbreak. The COVID-19 pandemic has affected clinical trials in an unparalleled manner due to multiple levels of restrictions imposed to control the spread of infection. However, with the rising demand for products to treat the COVID-19 infection, the biopharmaceutical and pharmaceutical companies in India and China have increased their research activities, which is positively impacting the market growth.
The liver is the largest internal organ in the human body and performs over 500 functions. Liver toxicity is a major concern in risk assessment as the liver is exposed to most xenobiotic compounds and their bioactive metabolites, making it susceptible to chemically induced liver disease. Hepatitis C virus (HCV), chronic hepatitis B virus (HBV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are among the leading causes of chronic liver disease. Viral hepatitis continues to be the leading cause of death cases caused by liver failure, and at the same time, the NAFLD has become one of the fastest-growing contributors to liver morbidity and associated mortality. According to the national statistics of the UK, liver diseases have been ranked the fifth-leading cause of death in the country.
Furthermore, these diseases are considered the second-leading cause of death among all digestive diseases in the US. According to the American Association for the Study of Liver Diseases, in 2017, the global burden of liver cancer and cirrhosis had increased. The NAFLDs have an estimated prevalence of ~25% in the general population. Nearly a third of the US population has the NAFLD, and people with Type 2 diabetes mellitus or obesity are disproportionately affected; the number of cases with NAFLD is expected to increase from 83.1 million people in 2015 to 100.9 million by 2030. Thus, a rise in the global prevalence of liver diseases, including chronic and acute diseases and microbial infections, increases the demand for liver models.
Based on type, the human liver models market is further segmented into liver organoids, liver-on-a-chip, 2D models, 3D bioprinting, and others. The liver organoids segment holds the largest share of the market. However, the liver-on-a-chip segment is anticipated to register the highest CAGR during 2021–2028. Advances in liver organoid technology provide models for prenatal development, tissue preservation, and pathologies, which would propel the market growth of this segment in the coming years.
Based on application, the human liver models market is further segmented into educational, drug discovery, and others. The drug discovery segment holds the largest share of the human liver models market; however, the educational segment is anticipated to register the highest CAGR during the forecast period.
Based on end user, the human liver models market is segmented into research institutes, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology companies segment holds the largest market share. However, the research institutes segment is estimated to register the highest CAGR during the forecast period. The projected market growth for this segment can be attributed to an increase in collaborations between industry and universities for genome research and technological advances in the production of human liver models.
Companies operating in the human liver models market are adopting product innovations strategy to meet the evolving customer demands worldwide, which also permits them to maintain their brand name in the global market.
The regional trends and factors influencing the Human Liver Models Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Human Liver Models Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 233.90 Million |
| Market Size by 2028 | US$ 508.26 Million |
| Global CAGR (2021 - 2028) | 11.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Human Liver Models Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Human Liver Models Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The liver-on-a-chip segment is growing at the highest CAGR owing to increasing demand for cost-effective alternatives to animal models for drug research and development.
Asia Pacific is expected to be the fastest growing region in the Human Liver Models market. The growth of the market in this region is primarily due to growing biopharmaceutical industry, increasing number of clinical trials, and increasing research activities for the development of innovative therapies.
North America dominates the global human liver models market due to factors such as increasing incidences of the liver diseases such as cirrhosis, chronic liver disease (CLD), Nonalcoholic fatty liver disease (NAFLD) and others across the country. Moreover, the growth of market in Canada is expected to grow due to increasing support from the government to address the rising concerns about the liver diseases.
The factors that are driving growth of the market are increasing prevalence of liver diseases, and growing focus on developing alternatives for animal testing models.
Various companies have made organic growth strategies in the human liver models market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as InSphero, Emulate, Inc amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.